STAT

Opinion: Unnecessary exclusions shut patients out of clinical trials

Many sick patients are being denied the opportunity to test new drugs that might save their lives. It’s time for this to change.

Not long ago, I examined an otherwise healthy and active man in his 50s with newly diagnosed metastatic lung cancer. He had no heart disease, no kidney disease, no liver disease. He came to my practice at UT Southwestern Medical Center specifically for clinical trial options.

Disappointingly, one detail in his medical history excluded him from all of our available trials. Four years for it. I couldn’t think of a single way in which the patient’s prior experience with cancer would interfere with treatments or assessments on a lung cancer trial. And yet I couldn’t enroll him.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Moderna Covid-flu Vaccine, A Paused Pfizer Study, And More
Moderna announced its combination Covid and flu vaccine generated stronger immune responses in older adults in a Phase 3 trial than individual vaccines.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Novo’s Wegovy Approval In China, A Merck KGaA Cancer Trial Failure, And More
Novo Nordisk's weight loss drug Wegovy has been approved in China, the country estimated to have the highest number of overweight or obese people.
STAT1 min readIntelligence (AI) & Semantics
STAT+: Q&A: Defining Responsible AI In Health Care, With CHAI CEO Brian Anderson
CHAI CEO Anderson wants to build public trust in AI and empower patients and providers to have more informed conversations.

Related Books & Audiobooks